Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07217678 · ClinicalTrials.gov registry record · Phase 4
Biomarkers of Ocular Surface Damage in the Setting of Topical Ocular Hypotensive Medication Use
A Phase 4 study of Glaucoma and Ocular Hypertension, sponsored by University of Miami.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT07217678: Recruiting Phase 4 study of Glaucoma and Ocular Hypertension, sponsored by University of Miami.
NCT07217678 is a Phase 4 study of Glaucoma and Ocular Hypertension that is actively recruiting participants, run by University of Miami. The registered enrollment target is 20 participants, below the 910-participant average among 92 other Glaucoma trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07217678, a Phase 4 study of Glaucoma and Ocular Hypertension, is actively recruiting participants, sponsored by University of Miami.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
The objective of this study is to evaluate whether reduction in topical medication with the injection of a sustained release capsule (Durysta) leads to a reduction in ocular surface inflammation, indicated by levels of caspase-1, an inflammatory biomarker.
Primary Outcome
The primary outcome is evaluating whether the level of caspase-1 from the ocular surface changes after the Durysta injection when the number of topical medications is reduced. Higher values indicate more inflammation, while lower values indicate less information and a more stable ocular surface. The Caspase-1 level will be measured using RT-PCR.
Conditions Studied
Interventions
- DRUG Durysta, Bimatoprost Intracameral Implant 10 µg
Study Locations (1)
Florida
- Bascom Palmer Eye Institute - Miami
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2026-02-09 |
| Est. Completion | 2028-01-31 |
| Phase | Phase 4 |
What NCT07217678 shows while recruiting
NCT07217678 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 910-participant average among 92 other Glaucoma trials with a reported enrollment target (98% lower).
The record links to 4 conditions, with Glaucoma appearing as the primary indexed condition, and to 1 intervention - of which Durysta, Bimatoprost Intracameral Implant 10 µg is the first listed.
NCT07217678 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT07217678 about?
NCT07217678 is a clinical study titled "Biomarkers of Ocular Surface Damage in the Setting of Topical Ocular Hypotensive Medication Use". The objective of this study is to evaluate whether reduction in topical medication with the injection of a sustained release capsule (Durysta) leads to a reduction in ocular surface inflammation, indicated by levels of caspase-1, an inflammatory biomarker.
What is the current status of trial NCT07217678?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 20 participants. The study started on 2026-02-09. Estimated completion is 2028-01-31.
What conditions does trial NCT07217678 study?
This clinical trial studies the following conditions: Glaucoma, Ocular Hypertension, Open Angle Glaucoma, Glaucoma, Suspect.
What interventions are being tested in trial NCT07217678?
The interventions under investigation include: Durysta, Bimatoprost Intracameral Implant 10 µg (DRUG).
Who is sponsoring clinical trial NCT07217678?
This trial is sponsored by University of Miami, which has 721 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07217678 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glaucoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07217678's enrollment target sits among peer trials
20 87th of 92 higher than 5 of 92 other Glaucoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Glaucoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Retinal Blood Flow and Autoregulation
RECRUITING · Phase 4
-
Evaluating Injection With the Use of Brimonidine Tartrate Ophthalmic 0.025% on Patients Using Netarsudil 0.02%/Latanoprost 0.005% to Treat Glaucoma
RECRUITING · Phase 4
-
Examining The Efficacy, Safety And Improved Tolerability Of Travoprost BAK Free Ophthalmic Solution (Travatan-Z) Compared To Prior Prostaglandin Therapy
COMPLETED · Phase 4
-
Efficacy of Bimatoprost 0.03% in Patients Who Are Low-Responders to Latanoprost
COMPLETED · Phase 4
-
Aqueous Humor Dynamic Components That Determine Intraocular Pressure Variance
COMPLETED · Phase 4
-
Bimatoprost 0.03% Versus Travoprost 0.004% in Patients Currently on Latanoprost 0.005%
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI